^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M701

    i
    Other names: M701
    Associations
    News

    Trials

    Company:
    YZY Biopharma
    Drug class:
    CD3 agonist, EPCAM inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (NCT06432296)
    Phase 3
    Wuhan YZY Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    03/20/2024
    Primary completion :
    08/03/2025
    Completion :
    11/11/2025
    EPCAM
    |
    M701
    A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (NCT05543330)
    Phase 1/2
    Wuhan YZY Biopharma Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/16/2022
    Initiation :
    09/30/2022
    Primary completion :
    06/01/2024
    Completion :
    12/01/2024
    EPCAM
    |
    EPCAM expression
    |
    cisplatin • M701
    A Study of M701 (EpCAM and CD3) in Malignant Ascites (NCT04501744)
    Phase 1
    Wuhan YZY Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    08/06/2020
    Initiation :
    10/30/2018
    Primary completion :
    01/31/2021
    Completion :
    06/30/2021
    CEACAM5 • MUC16 • AFP • CA 19-9
    |
    CEACAM5 expression • MUC16 expression
    |
    M701